Cargando…
Prothrombotic Milieu, Thrombotic Events and Prophylactic Anticoagulation in Hospitalized COVID-19 Positive Patients: A Review
The Coronavirus Disease 2019 (COVID-19) pandemic has resulted in significant morbidity and mortality worldwide. Although initial reports concentrated on severe respiratory illness, emerging literature has indicated a substantially elevated risk of thromboembolic events in patients with COVID-19 dise...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8793375/ https://www.ncbi.nlm.nih.gov/pubmed/35068227 http://dx.doi.org/10.1177/10760296221074353 |
_version_ | 1784640584816787456 |
---|---|
author | Cryer, Michael Joseph Farhan, Serdar Kaufmann, Christoph C. Jäger, Bernhard Garg, Aakash Krishnan, Prakash Mehran, Roxana Huber, Kurt |
author_facet | Cryer, Michael Joseph Farhan, Serdar Kaufmann, Christoph C. Jäger, Bernhard Garg, Aakash Krishnan, Prakash Mehran, Roxana Huber, Kurt |
author_sort | Cryer, Michael Joseph |
collection | PubMed |
description | The Coronavirus Disease 2019 (COVID-19) pandemic has resulted in significant morbidity and mortality worldwide. Although initial reports concentrated on severe respiratory illness, emerging literature has indicated a substantially elevated risk of thromboembolic events in patients with COVID-19 disease. Pro-inflammatory cytokine release has been linked to endothelial dysfunction and activation of coagulation pathways, as evident by elevated D-dimer levels and deranged coagulation parameters. Both macrovascular and microvascular thromboses have been described in observational cohort and post-mortem studies. Concurrently, preliminary data have suggested the role of therapeutic anticoagulation in preventing major thromboembolic complications in moderately but not critically ill patients. However, pending results from randomized controlled trials, clear guidance is lacking regarding the intensity and duration of anticoagulation in such patients. Herein, we review the existing evidence on incidence and pathophysiology of COVID-19 related thromboembolic complications and guide anticoagulation therapy based on current literature and societal consensus statements. |
format | Online Article Text |
id | pubmed-8793375 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | SAGE Publications |
record_format | MEDLINE/PubMed |
spelling | pubmed-87933752022-01-28 Prothrombotic Milieu, Thrombotic Events and Prophylactic Anticoagulation in Hospitalized COVID-19 Positive Patients: A Review Cryer, Michael Joseph Farhan, Serdar Kaufmann, Christoph C. Jäger, Bernhard Garg, Aakash Krishnan, Prakash Mehran, Roxana Huber, Kurt Clin Appl Thromb Hemost Review The Coronavirus Disease 2019 (COVID-19) pandemic has resulted in significant morbidity and mortality worldwide. Although initial reports concentrated on severe respiratory illness, emerging literature has indicated a substantially elevated risk of thromboembolic events in patients with COVID-19 disease. Pro-inflammatory cytokine release has been linked to endothelial dysfunction and activation of coagulation pathways, as evident by elevated D-dimer levels and deranged coagulation parameters. Both macrovascular and microvascular thromboses have been described in observational cohort and post-mortem studies. Concurrently, preliminary data have suggested the role of therapeutic anticoagulation in preventing major thromboembolic complications in moderately but not critically ill patients. However, pending results from randomized controlled trials, clear guidance is lacking regarding the intensity and duration of anticoagulation in such patients. Herein, we review the existing evidence on incidence and pathophysiology of COVID-19 related thromboembolic complications and guide anticoagulation therapy based on current literature and societal consensus statements. SAGE Publications 2022-01-24 /pmc/articles/PMC8793375/ /pubmed/35068227 http://dx.doi.org/10.1177/10760296221074353 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by-nc/4.0/This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access page (https://us.sagepub.com/en-us/nam/open-access-at-sage). |
spellingShingle | Review Cryer, Michael Joseph Farhan, Serdar Kaufmann, Christoph C. Jäger, Bernhard Garg, Aakash Krishnan, Prakash Mehran, Roxana Huber, Kurt Prothrombotic Milieu, Thrombotic Events and Prophylactic Anticoagulation in Hospitalized COVID-19 Positive Patients: A Review |
title | Prothrombotic Milieu, Thrombotic Events and Prophylactic Anticoagulation in Hospitalized COVID-19 Positive Patients: A Review |
title_full | Prothrombotic Milieu, Thrombotic Events and Prophylactic Anticoagulation in Hospitalized COVID-19 Positive Patients: A Review |
title_fullStr | Prothrombotic Milieu, Thrombotic Events and Prophylactic Anticoagulation in Hospitalized COVID-19 Positive Patients: A Review |
title_full_unstemmed | Prothrombotic Milieu, Thrombotic Events and Prophylactic Anticoagulation in Hospitalized COVID-19 Positive Patients: A Review |
title_short | Prothrombotic Milieu, Thrombotic Events and Prophylactic Anticoagulation in Hospitalized COVID-19 Positive Patients: A Review |
title_sort | prothrombotic milieu, thrombotic events and prophylactic anticoagulation in hospitalized covid-19 positive patients: a review |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8793375/ https://www.ncbi.nlm.nih.gov/pubmed/35068227 http://dx.doi.org/10.1177/10760296221074353 |
work_keys_str_mv | AT cryermichaeljoseph prothromboticmilieuthromboticeventsandprophylacticanticoagulationinhospitalizedcovid19positivepatientsareview AT farhanserdar prothromboticmilieuthromboticeventsandprophylacticanticoagulationinhospitalizedcovid19positivepatientsareview AT kaufmannchristophc prothromboticmilieuthromboticeventsandprophylacticanticoagulationinhospitalizedcovid19positivepatientsareview AT jagerbernhard prothromboticmilieuthromboticeventsandprophylacticanticoagulationinhospitalizedcovid19positivepatientsareview AT gargaakash prothromboticmilieuthromboticeventsandprophylacticanticoagulationinhospitalizedcovid19positivepatientsareview AT krishnanprakash prothromboticmilieuthromboticeventsandprophylacticanticoagulationinhospitalizedcovid19positivepatientsareview AT mehranroxana prothromboticmilieuthromboticeventsandprophylacticanticoagulationinhospitalizedcovid19positivepatientsareview AT huberkurt prothromboticmilieuthromboticeventsandprophylacticanticoagulationinhospitalizedcovid19positivepatientsareview |